Drug Shortage Report for SANDOZ IRBESARTAN HCT
Report ID | 129102 |
Drug Identification Number | 02337428 |
Brand name | SANDOZ IRBESARTAN HCT |
Common or Proper name | SANDOZ IRBESARTAN HCT |
Company Name | SANDOZ CANADA INCORPORATED |
Market Status | MARKETED |
Active Ingredient(s) | IRBESARTAN HYDROCHLOROTHIAZIDE |
Strength(s) | 150MG 12.5MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 500 FCT BO |
ATC code | C09DA |
ATC description | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
Reason for shortage | Requirements related to complying with good manufacturing practices. |
Anticipated start date | |
Actual start date | 2020-11-27 |
Estimated end date | |
Actual end date | 2020-12-04 |
Shortage status | Resolved |
Updated date | 2020-12-09 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2020-11-27 | English | Compare |
v2 | 2020-11-27 | French | Compare |
v3 | 2020-11-28 | English | Compare |
v4 | 2020-12-09 | English | Compare |
v5 | 2020-12-09 | French | Compare |
Showing 1 to 5 of 5